List of biotin-PAA-glycans (fifty-two) used in glycan solution microarray [28].
1. Introduction
Glycosylation adorns more than one half of the proteins in eukaryotic cells [1,2]. This post-translational modification plays an indispensible role in many important biological events, especially on cell surface [1,3]. Alterations in carbohydrate structures are known to correlate with the changes in protein stability and clearance, as well as various physiological functions including cell-cell adhesion, inflammation, tumor metastasis, and infection of bacteria and viruses [4-8]. Although glycosylation is essential for the formation and progression of various diseases, study of this subject is hampered by lack of effective tools available to date, in addition to structural heterogeneity and complexity of carbohydrates. A number of techniques have been developed to analyze the binding interactions between carbohydrates and proteins [2,9]. For instances, lectin blotting/binding assay has become a routine method to determine the glycan-protein interactions [10], but the relatively low sensitivity and the necessity of multiple wash steps/time-consuming have restricted the sensitivity and application. Surface plasmon resonance is another highly sensitive method which monitors the interactions in real time and in a quantitative manner [11-16]. However, sometimes the sensitivity is relatively low toward the use of low molecular-weight carbohydrates, though the problem can be overcome by labeling sugars with heavy metal ions [17]. In addition, fluorescence polarization and two-photon fluorescence correlation have been applied to study lectin-glycan interactions [18-21]. The most applicable technique is carbohydrate microarrays which immobilize oligosaccharides to a solid supports are developed and widely used to measure the carbohydrate binding properties of proteins, cells, or viruses [22-25]. For example, a high-content glycan microarray is developed by a robotic microarray printing technology in which amine-functionalized glycans are coupled to the succinimide esters on glass slides [26,27]. These microarrays have also been subjected for profiling the carbohydrate binding specificities of lectins, antibodies, and intact viruses.
2. Carbohydrate microarray
In our recent work, we have developed two novel carbohydrate microarrays: solution microarray [28] and membrane microarray [29]. Carbohydrate solution assay is a high-throughput, homogenous and sensitive method to characterize protein-carbohydrate interactions and glycostructures by in-solution proximity binding with photosensitizers (Figure 1). The technology, also called AlphaScreenTM, is first described by Ullman et al., and has been used to study interactions between biomolecules [30-34]. In these assays, a light signal is generated when a donor bead and an acceptor bead are brought into proximity. This method usually provides good sensitivity with
Carbohydrate membrane microarray is fabricated by immobilization of the biotin-conjugated PAA-based glycans on aldehyde-functionalized UltraBind via streptavidin. Streptavidin interacted strongly with biotin and formed covalent linkage with membranes after reductive amination, which prevented the loss of glycans from membrane during repeated wash steps. The use of PAA also avoided the nonspecific interactions that take place in other studies between some lectins and non-glycosylated proteins (e.g. HAS or BSA) [35]. The operation of this carbohydrate membrane microarray is similar to that of Western blotting and can be performed easily by anyone without prior intensive training.
3. Applications
3.1. Carbohydrate binding profiles of lectins and antibodies (solution microarray)
Fifty-four biotinylated polyacrylamide backboned glycans (biotin-PAA-glycans) (Table 1) are collected in total to examine fifteen carbohydrate-binding proteins, including eight lectins (Con A, DBA, GS-I, PNA, SBA, UEA-1, WFA and WGA), and six antibodies (anti-Lea, Leb, Lex, Ley, sialyl Lea and sialyl Lex). The resulting signals are indicated with bars as relative intensities (Figures 2 and 3). The natural carbohydrate ligands for these lectins are listed in Table 2. All of the lectins showed nearly the same carbohydrate binding preferences as those in literatures. For example, concanavalin A (Con A) bound preferentially to mannose (No. 3) and biantennary
3.2. Binding patterns of seventeen lectins and four antibodies (membrane microarray)
The principle and procedures of carbohydrate membrane microarray are showed in Figure 4. The western blotting like procedures not only reduces the time and interference, but also increases the application of this platform. In order to look deep inside the carbohydrate binding preferences of proteins and microorganisms, the collections of biotin-PAA-glycans were to increased eighty-eight different structures (Table 3). The glycan binding specificities of sixteen lectins (six alkaline phosphatase (AP)-conjugated lectins, four FITC-conjugated lectins, six unconjugated lectins) and four Lewis blood-group antibodies are evaluated and showed in Figures 5 and 6. All the lectins recognized the glycans that are consistent with the literature. For instance, ECA preferentially interacted with LacNAc, lactose, GalNAc, and Gal terminal sugars; PNA specifically bound to the Galβ1-3GalNAc structure; SBA dominantly recognized α-linked GalNAc epitopes; 3-sulfate LacNAc is ligand for MAA [36]. Compare the patterns of unconjugated lectins with conjugated lectins (AP- or FITC-attached) indicated that the glycan preferences of ECA and PNA are not interfered by conjugation. More binding signals are observed in the binding profiles of AP-conjugated MAA, SBA and WGA compared with unconjugated or FITC-attached ones. Additionally, the binding patterns of DBA, ECA, GS-I, MAA, SBA and VVA are highly consistent with those reported by Consortium for Functional Glycomics (CFG, printed microarray Ver. 2,). However, few inconsistencies are also observed in the study of MPA, PNA, UEA and WGA. Furthermore, the binding patterns of four Lewis blood group antibodies represented very high specificities (Figure 6).
S-1 | Blank-PAA-biotin | S-46 | Neu5Acα2-6Galβ-PAA-biotin |
S-2 | β-GlcNAc-sp-biotin | S-47 | Neu5Gcα2-6GalNAc-PAA-biotin |
S-3 | α-Mannose-PAA-biotin | S-48 | Neu5Acα2-3GalNAcα-PAA-biotin |
S-4 | β-GlcNAc-PAA-biotin | S-49 | Blood Group A-tri-PAA-biotin |
S-5 | β-GalNAc-PAA-biotin | S-50 | Blood Group B-tri-PAA-biotin |
S-6 | α-L-Fuc-PAA-biotin | S-51 | H(type2)-PAA-biotin |
S-7 | α-Neu5Ac-PAA-biotin | S-52 | Lea-PAA-biotin |
S-8 | α-Neu5Ac-OCH2C6H4-p-NHCOOCH2-PAA-biotin | S-53 | Lex-PAA-biotin |
S-9 | MDP(muramyl dipeptide)-PAA-biotin | S-54 | Led(H type1)-PAA-biotin |
S-10 | α-Neu5Gc-PAA-biotin | S-55 | 3'Sialyl-Lactose-PAA-biotin |
S-11 | β-D-Gal-3-sulfate-PAA-biotin | S-56 | 6'Sialyl-Lactose-PAA-biotin |
S-12 | β-D-GlcNAc-6-sulfate-PAA-biotin | S-57 | 3-HSO3-Lex-PAA-biotin |
S-13 | GalNAcα1-3Galβ-PAA-biotin | S-58 | 3-HSO3-Lea-PAA-biotin |
S-14 | Galα1-3Galβ-PAA-biotin | S-59 | Galα1-4Galβ1-4Glcβ-PAA-biotin |
S-15 | Fucα1-2Galβ-PAA-biotion | S-60 | Galα1-3Galβ1-4Glcβ-PAA-biotin |
S-16 | Lec(Galβ1-3GlcNAc)-PAA-biotin | S-61 | GlcNAcβ1-2Galβ1-3GalNAcα-PAA-biotin |
S-17 | Galβ1-4Glcβ-PAA-biotin (Lactose) | S-62 | Neu5Acα2-3Galβ1-4GlcNAcβ-PAA-Biotin |
S-18 | LacNAc-PAA-biotin | S-63 | 3'Sialyl-Lec-PAA-biotin |
S-19 | Fucα1-3GlcNAcβ-PAA-biotin | S-64 | Galα1-3Galβ1-4GlcNAcβ-PAA-biotin, sp=-NHCOCH2NH- |
S-20 | Fucα1-4GlcNAcβ-PAA-biotin | S-65 | GlcNAcα1-3Galβ1-3GalNAcα-PAA-biotin |
S-21 | GalNAcα1-3GalNAcα-PAA-biotin | S-66 | GlcNAcβ1-3Galβ1-3GalNAcα-PAA-biotin |
S-22 | Galα1-3GalNAcα-PAA-biotin | S-67 | Galβ1-3(GlcNAcβ1-6)GalNAcα-PAA-biotin |
S-23 | Galβ1-3GalNAcβ-PAA-biotin | S-68 | Blood type A (tri)-PAA-biotin, sp=(CH2)3NHCO(CH2)5NH- |
S-24 | Galα1-3GalNAcβ-PAA-biotin | S-69 | Blood type B (tri)-PAA-biotin, sp=(CH2)3NHCO(CH2)5NH- |
S-25 | Galβ1-3Galβ-PAA-biotin | S-70 | GlcNAcb1-3Galβ1-4GlcNAc-PAA-biotin |
S-26 | GlcNAcβ1-3Galβ-PAA-biotin | S-71 | Neu5Acα2-3Galβ1-3GalNAcα-PAA-Biotin |
S-27 | αLacNAc-PAA-biotin | S-72 | GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα-PAA-biotin |
S-28 | Glcα1-4Glcβ-PAA-biotin | S-73 | Galα1-4Galβ1-4GlcNAcβ-PAA-biotin |
S-29 | Galβ1-3GalNAcα-PAA-biotin, sp=-p-OC6H4- | S-74 | GlcNAcβ1-4GlcNAcβ1-4GlcNAc-PAA-biotin |
S-30 | Galα1-2Galβ-PAA-biotin | S-75 | Galβ1-3(Neu5Acα2-6)GalNAcα-PAA-biotin |
S-31 | GlcNAcβ1-4GlcNAc-PAA-biotin | S-76 | Neu5Acα2-3(Neu5Acα2-6)GalNAc-PAA-biotin |
S-32 | GlcNAcβ1-4GlcNAcβ-PAA-biotin, sp=-NHCOCH2NH- | S-77 | Galβ1-4GlcNAcβ1-3GalNAcα-PAA-biotin |
S-33 | Neu5Acα2-6GalNAc-PAA-biotin | S-78 | Leb-PAA-biotin |
S-34 | H(type 3)-PAA-biotin | S-79 | Ley-PAA-biotin |
S-35 | 3-HSO3-Galβ1-4GlcNAc-PAA-biotin | S-80 | Sialyl Lea-PAA-biotin |
S-36 | 3-HSO3-Galβ1-3GlcNAcβ-PAA-biotin | S-81 | Sialyl Lex-PAA-biotin |
S-37 | Galα1-6Glcβ-PAA-biotin (melibiose) | S-82 | GlcNAcβ1-3(GlcNAcβ1-6)Galβ1-4Glcβ-PAA-biotin |
S-38 | Neu5Acα2-8Neu5Acα-sp**-PAA-biotin, (Neu5Ac)2 | S-83 | Galα1-3(Fucα1-2)Galβ1-4GlcNAc-PAA-biotin |
S-39 | Galβ1-2Galβ-PAA-biotin | S-84 | Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ-PAA-biotin |
S-40 | 6-HSO3-Galβ1-4GlcNAc-PAA-biotin | S-85 | Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-PAA-biotin |
S-41 | Neu5Acα2-3Gal-PAA-biotin | S-86 | (NeuAcα2-8)5-6-PAA-biotin |
S-42 | Galβ1-4(6-HSO3)GlcNAcb-PAA-biotin | S-87 | Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcα-PAA-biotin |
S-43 | 3-HSO3-Galβ1-3GalNAcβ-PAA-biotin (sulfate-TF) | S-88 | α2-6 sialylated diantennary N-glycans-PAA-biotin |
S-44 | GlcNAcβ1-3GalNAcα-PAA-biotin | S-89 | GalNAc-α-Ser-PAA-biotin |
S-45 | GlcNAcβ1-6GalNAcα-PAA-biotin | S-90 | H2O |
3.3. Surveillance of seasonal and pandemic H1N1 influenza A viruses (membrane microarray)
Several methods are applied for exploring the carbohydrate-binding preference of influenza viruses or recombinant HA, including cell-based assays [37-39], immobilization of virus [40-46] and glycan microarray technology [47-49]. In our study, 30 biotin-PAA-glycans (Table 4, most of them were sulfated and sialylated) were selected and fabricated on membrane and applied for the carbohydrate ligand surveillance of influenza clinical isolates. We subjected this influenza membrane microarray to characterize the glycan-binding features of five seasonal influenza A (H1N1) and seven A(H1N1)pdm09 clinical isolates. The binding patterns of all studied viruses are successfully profiled, with each virus exhibiting different and clear patterns, thereby enabling characterization (Figure 7, Lane 1 to 12). The majority of the seasonal H1N1 viruses bound strongly to 6'-sialyl lactose and sialyl biantennary
I-1 | Blank-PAA-biotin | I-17 | Neu5Gcα2-6GalNAc-PAA-biotin |
I-2 | α-Neu5Ac-PAA-biotin | I-18 | Neu5Acα2-3GalNAcα-PAA-biotin |
I-3 | α-Neu5Ac-OCH2C6H4-p-NHCOOCH2-PAA-biotin | I-19 | 3'Sialyl-Lactose-PAA-biotin |
I-4 | MDP(muramyl dipeptide)-PAA-biotin | I-20 | 6'Sialyl-Lactose-PAA-biotin |
I-5 | α-Neu5Gc-PAA-biotin | I-21 | 3-HSO3-Lex-PAA-biotin |
I-6 | β-D-Gal-3-sulfate-PAA-biotin | I-22 | 3-HSO3-Lea-PAA-biotin |
I-7 | β-D-GlcNAc-6-sulfate-PAA-biotin | I-23 | Neu5Acα2-3Galβ1-4GlcNAcβ-PAA-Biotin |
I-8 | Neu5Acα2-6GalNAc-PAA-biotin | I-24 | 3'Sialyl-Lec-PAA-biotin |
I-9 | 3-HSO3-Galβ1-4GlcNAc-PAA-biotin | I-25 | Neu5Acα2-3Galβ1-3GalNAcα-PAA-Biotin |
I-10 | 3-HSO3-Galβ1-3GlcNAcβ-PAA-biotin | I-26 | Galβ1-3(Neu5Acα2-6)GalNAcα-PAA-biotin |
I-11 | Neu5Acα2-8Neu5Acα-sp**-PAA-biotin, (Neu5Ac)2 | I-27 | Neu5Acα2-3(Neu5Acα2-6)GalNAc-PAA-biotin |
I-12 | 6-HSO3-Galβ1-4GlcNAc-PAA-biotin | I-28 | Sialyl Lea-PAA-biotin |
I-13 | Neu5Acα2-3Gal-PAA-biotin | I-29 | Sialyl Lex-PAA-biotin |
I-14 | Galβ1-4(6-HSO3)GlcNAcb-PAA-biotin | I-30 | (NeuAcα2-8)5-6-PAA-biotin |
I-15 | 3-HSO3-Galβ1-3GalNAcβ-PAA-biotin (sulfate-TF) | I-31 | α2-6 sialylated diantennary N-glycans -PAA-biotin |
I-16 | Neu5Acα2-6Galβ-PAA-biotin | I-32 | H2O |
3.4. Surveillance of influenza B clinical isolates (membrane microarray)
The influenza carbohydrate membrane microarray is subsequently subjected for the surveillance of twelve influenza B (IB) clinical isolates [50]. All of the viruses are collected in the Clinical Virology Laboratory of National Cheng Kung University Hospital between 2001 and 2004. The clinical isolates are amplified in MDCK cells and purified by a sucrose gradient. The binding patterns of the influenza B viruses are investigated and are all found to exhibit clear binding profiles (Figure 8). Three common glycans, including α-Neu5Ac (
The DNA sequences of hemagglutinin of the twelve influenza B clinical isolates were analyzed, translated into sequences of amino acids, and aligned with B/HongKong/8/73, Victoria (B/Victoria/02/87), and Yamagata (B/Yamagata/16/88) lineages using online software EBI ClustalW2. Surprisingly, the twelve influenza B clinical isolates could all be categorized into two groups depending on protein sequence alignment. Group 1 contained eight clinical isolates (B/Taiwan/314/2001, B/Taiwan/174/2002, B/Taiwan/288/2002, B/Taiwan/1729/2002, B/Taiwan/1994/2002, B/Taiwan/872/2004, B/Taiwan/913/2004 and B/Taiwan/1902/2004, Figure 8, Table 5) and Group 2 contained four viruses (B/Taiwan/262/2001, B/Taiwan/925/2001, B/Taiwan/966/2001, B/Taiwan/2284/2001). We found that all of the viruses in group 2 were isolated in 2001. In addition, there were twelve amino acid differences between the two groups. Most of the amino acids were located at the chain region and subunit interfaces, while four amino acids were located within the antigenic site (loop 160, amino acid number of B/HK/73) [51,52]. Additionally, four amino acids changed the charge property from group 1 to group 2 viruses (Table 5, No. 56, 116, 181 and 182, amino acid number of B/Yamagata/16/88). Different carbohydrate binding properties were also observed between some viruses of the two groups. Specifically, group 2 viruses interacted with three major sialylated glycans, while some of group 1 viruses bound not only strongly to the three glycans, but also weakly to sulfated and α2-3 sialylated glycans. Additionally, the number of charged amino acids was higher in group 2 than in group 1 viruses and B/HongKong/8/73 (Table 5).
According to the binding preference for α2-6 and α2-3 sialylated oligosaccharides displayed by these clinical isolated influenza viruses, these clinical isolates might infect not only the surface of nasal mucosa, pharynx, larynx, trachea and bronchi (that are resided in the upper respiratory tract to express α2-6 sialosides predominantly), but also alveoli, bronchi (that are located in the lower respiratory tract), eyes, and tissues in the gastrointestinal tract (that contain both α2-3 and α2-6 sialosides) [53,54]. After we surveyed more clinical isolates, factors which affect the binding preference of IB could be dissected. We believe that application of the carbohydrate microarray for detailed analysis of sugar-binding structures will eventually build the connection between clinical symptoms and the genetic specification of influenza viruses.
3.5. Characterization the glycan structure of glycoproteins (solution microarray)
The aforementioned lectins are further applied to characterize the glycan structures of six biotinylated proteins including ovalbumin, porcine mucin, human serum albumin, human transferrin, fetuin and asialofetuin. Distinctive glycopatterns are generated in accordance with the analysis of lectins (Figure 9). Porcine mucin is known to have
4. Perspective
In summary, carbohydrate-protein interactions are the key steps for many physiological and pathological evens. Hence, development of new carbohydrate microarrays is important for detecting these activities. Our studies have demonstrated a rapid, highly sensitive, and reliable method to characterize carbohydrate-protein interactions with minimized materials (in the range of ng per well). Lectins and antibodies are evaluated and most of the results are coherent to previous reports, including those of CFG. Solution microarray is the first homogeneous and washless carbohydrate microarray which offers a reliable alternative for characterizing sugar-binding features of lectins and proteins, as well as antibodies. In addition, membrane microarray is also easy handled with low cost (USD$0.25 for one membrane microarray). The easy-handling feature avoids the necessity of repetitive training and accelerates the screening efficiency. Both of the microarrays represent a convenient and reliable way to examine the carbohydrate-binding features of various proteins, high-throughput drug screening, and the glycan binding surveillance of influenza viruses.
References
- 1.
Varki A. 1993 Glycobiology3 97 130 - 2.
Ratner D. M. Adams E. W. Disney M. D. Seeberger P. H. 2004 Chembiochem5 1375 1383 - 3.
Fukuda M. 2000 Molecular and Cellular Glycobiology, Oxford University Press - 4.
Magnani J. L. Brockhaus M. Smith D. F. Ginsburg V. Blaszczyk M. Mitchell K. F. Steplewski Z. Koprowski H. 1981 Science212 55 56 - 5.
Sacchettini J. C. Baum L. G. Brewer C. F. 2001 Biochemistry40 3009 3015 - 6.
Kansas G. S. 1996 Blood88 3259 3287 - 7.
Geijtenbeek T. B. Torensma R. van Vliet S. J. van Duijnhoven G. C. Adema G. J. van Kooyk Y. Figdor C. G. 2000 Cell100 575 585 - 8.
Skehel J. J. Wiley D. C. 2000 Annu Rev Biochem69 531 569 - 9.
Raman R. Raguram S. Venkataraman G. Paulson J. C. Sasisekharan R. 2005 Nat Methods2 817 824 - 10.
Wu A. M. 2001 The Molecular Immunology of Complex Carbohydreats-2, Kluwer Academic/Plenum Publishers - 11.
Ratner D. M. Adams E. W. Su J. O’Keefe B. R. Mrksich M. Seeberger P. H. 2004 Chembiochem5 379 382 - 12.
Smith E. A. Thomas W. D. Kiessling L. L. Corn R. M. 2003 J Am Chem Soc125 6140 6148 - 13.
Vila-Perello M. Gutierrez Gallego. R. Andreu D. 2005 Chembiochem6 1831 1838 - 14.
Ofokansi K. C. Okorie O. Adikwu M. U. 2009 Biol Pharm Bull32 1754 1759 - 15.
Sletmoen M. Dam T. K. Gerken T. A. Stokke B. T. Brewer C. F. 2009 Biopolymers91 719 728 - 16.
Tian P. Engelbrektson A. Mandrell R. 2008 Appl Environ Microbiol74 4271 4276 - 17.
Beccati D. Halkes K. M. Batema G. D. Guillena G. Carvalho de Souza. A. van Koten G. Kamerling J. P. 2005 Chembiochem6 1196 1203 - 18.
Pohl W. H. Hellmuth H. Hilbert M. Seibel J. Walla P. J. 2006 Chembiochem7 268 274 - 19.
Khan M. I. Surolia N. Mathew M. K. Balaram P. Surolia A. 1981 Eur J Biochem115 149 152 - 20.
Lee Y. C. 2001 Anal Biochem297 123 127 - 21.
Sorme P. Kahl-Knutsson B. Huflejt M. Nilsson U. J. Leffler H. 2004 Anal Biochem334 36 47 - 22.
Fukui S. Feizi T. Galustian C. Lawson A. M. Chai W. 2002 Nat Biotechnol20 1011 1017 - 23.
Huang C. Y. Thayer D. A. Chang A. Y. Best M. D. Hoffmann J. Head S. Wong C. H. 2006 Proc Natl Acad Sci U S A103 15 20 - 24.
Feizi T. Fazio F. Chai W. Wong C. H. 2003 Curr Opin Struct Biol13 637 645 - 25.
Shin I. Park S. Lee M. R. 2005 Chemistry11 2894 2901 - 26.
Blixt O. Head S. Mondala T. Scanlan C. Huflejt M. E. Alvarez R. Bryan M. C. Fazio F. Calarese D. Stevens J. Razi N. Stevens D. J. Skehel J. J. van Die I. Burton D. R. Wilson I. A. Cummings R. Bovin N. Wong C. H. Paulson J. C. 2004 Proc Natl Acad Sci U S A101 17033 17038 - 27.
Wong C. H. 2005 J Org Chem70 4219 4225 - 28.
Chang C. F. Pan J. F. Lin C. N. Wu I. L. Wong C. H. Lin C. H. 2011 Glycobiology21 895 902 - 29.
Lao W. I. Wang Y. F. Kuo Y. D. Lin C. H. Chang T. C. Su I. J. Wang J. R. Chang C. F. 2011 Future Med Chem3 283 296 - 30.
Ullman E. F. Kirakossian H. Singh S. Wu Z. P. Irvin B. R. Pease J. S. Switchenko A. C. Irvine J. D. Dafforn A. Skold C. N. et al. 1994 Proc Natl Acad Sci U S A91 5426 5430 - 31.
Ullman E. F. Kirakossian H. Switchenko A. C. Ishkanian J. Ericson M. Wartchow C. A. Pirio M. Pease J. Irvin B. R. Singh S. Singh R. Patel R. Dafforn A. Davalian D. Skold C. Kurn N. Wagner D. B. 1996 Clin Chem42 1518 1526 - 32.
Warner G. Illy C. Pedro L. Roby P. Bosse R. 2004 Curr Med Chem11 721 730 - 33.
Bouchecareilh M. Caruso M. E. Roby P. Parent S. Rouleau N. Taouji S. Pluquet O. Bosse R. Moenner M. Chevet E. 2010 J Biomol Screen15 406 417 - 34.
Yi F. Zhu P. Southall N. Inglese J. Austin C. P. Zheng W. Regan L. 2009 J Biomol Screen14 273 281 - 35.
Manimala J. C. Roach T. A. Li Z. Gildersleeve J. C. 2006 Angew Chem Int Ed Engl45 3607 3610 - 36.
Bai X. Brown J. R. Varki A. Esko J. D. 2001 Glycobiology11 621 632 - 37.
Rogers G. N. D’Souza B. L. 1989 Virology173 317 322 - 38.
Suzuki Y. Nagao Y. Kato H. Suzuki T. Matsumoto M. Murayama J. 1987 Biochim Biophys Acta903 417 424 - 39.
Suptawiwat O. Kongchanagul A. Chan-It W. Thitithanyanont A. Wiriyarat W. Chaichuen K. Songserm T. Suzuki Y. Puthavathana P. Auewarakul P. 2008 J Clin Virol42 186 189 - 40.
Gambaryan A. S. Tuzikov A. B. Piskarev V. E. Yamnikova S. S. Lvov D. K. Robertson J. S. Bovin N. V. Matrosovich M. N. 1997 Virology232 345 350 - 41.
Gambaryan A. S. Matrosovich M. N. 1992 J Virol Methods39 111 123 - 42.
Sauter N. K. Hanson J. E. Glick G. D. Brown J. H. Crowther R. L. Park S. J. Skehel J. J. Wiley D. C. 1992 Biochemistry31 9609 9621 - 43.
Auewarakul P. Suptawiwat O. Kongchanagul A. Sangma C. Suzuki Y. Ungchusak K. Louisirirotchanakul S. Lerdsamran H. Pooruk P. Thitithanyanont A. Pittayawonganon C. Guo C. T. Hiramatsu H. Jampangern W. Chunsutthiwat S. Puthavathana P. 2007 J Virol81 9950 9955 - 44.
Yamada S. Suzuki Y. Suzuki T. Le M. Q. Nidom C. A. Sakai-Tagawa Y. Muramoto Y. Ito M. Kiso M. Horimoto T. Shinya K. Sawada T. Usui T. Murata T. Lin Y. Hay A. Haire L. F. Stevens D. J. Russell R. J. Gamblin S. J. Skehel J. J. Kawaoka Y. 2006 Nature444 378 382 - 45.
Gambaryan A. Yamnikova S. Lvov D. Tuzikov A. Chinarev A. Pazynina G. Webster R. Matrosovich M. Bovin N. 2005 Virology334 276 283 - 46.
Gambaryan A. S. Tuzikov A. B. Pazynina G. V. Webster R. G. Matrosovich M. N. Bovin N. V. 2004 Virology326 310 316 - 47.
Gall A. Hoffmann B. Harder T. Grund C. Hoper D. Beer M. 2009 J Clin Microbiol47 327 334 - 48.
Stevens J. Blixt O. Paulson J. C. Wilson I. A. 2006 Nat Rev Microbiol4 857 864 - 49.
Stevens J. Blixt O. Glaser L. Taubenberger J. K. Palese P. Paulson J. C. Wilson I. A. 2006 J Mol Biol355 1143 1155 - 50.
Wang Y. F. Lao W. I. Kuo Y. D. Guu S. Y. Wang H. C. Lin C. H. Wang J. R. Su I. J. Chang C. F. 2012 Fut Virol 7, 13 - 51.
Wang Q. Cheng F. Lu M. Tian X. Ma J. 2008 J Virol82 3011 3020 - 52.
Wang Q. Tian X. Chen X. Ma J. 2007 Proc Natl Acad Sci U S A104 16874 16879 - 53.
Kumlin U. Olofsson S. Dimock K. Arnberg N. 2008 Influenza and Other Respiratory Viruses 2, 8 - 54.
Kogure T. Suzuki T. Takahashi T. Miyamoto D. Hidari K. I. Guo C. T. Ito T. Kawaoka Y. Suzuki Y. 2006 Glycoconj J23 101 106 - 55.
Kolarich D. Altmann F. 2000 Anal Biochem285 64 75 - 56.
Pilobello K. T. Krishnamoorthy L. Slawek D. Mahal L. K. 2005 Chembiochem6 985 989 - 57.
Yang S. N. Liu C. A. Chung M. Y. Huang H. C. Yeh G. C. Wong C. S. Lin W. W. Yang C. H. Tao P. L. 2006 Hippocampus16 521 530 - 58.
Karlsson N. G. Packer N. H. 2002 Anal Biochem305 173 185 - 59.
Angeloni S. Ridet J. L. Kusy N. Gao H. Crevoisier F. Guinchard S. Kochhar S. Sigrist H. Sprenger N. 2005 Glycobiology15 31 41